Compare · AIKI vs KVUE
AIKI vs KVUE
Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Kenvue Inc. (KVUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIKI and KVUE operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- KVUE is the larger of the two at $35.86B, about 835.2x AIKI ($42.9M).
- KVUE has hit the wire 15 times in the past 4 weeks while AIKI has been quiet.
- KVUE has more recent analyst coverage (25 ratings vs 1 for AIKI).
- Company
- AIkido Pharma Inc.
- Kenvue Inc.
- Price
- $3.61+2.56%
- $18.90+1.29%
- Market cap
- $42.9M
- $35.86B
- 1M return
- -
- +5.70%
- 1Y return
- -
- +26.34%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 0
- 15
- Recent ratings
- 1
- 25
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Latest AIKI
- SEC Form SC 13D filed by AIkido Pharma Inc.
- SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)
- Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)
- Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)
- Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)
- Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)
- AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update
- Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)
- Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)
- Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)
Latest KVUE
- SEC Form 8-K filed by Kenvue Inc.
- Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
- LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion